148 Results for "

Type V

" in MedChemExpress (MCE) Product Catalog:
Products (148)

148 Results for "Type V" in MCE Product Catalog:

28
28 Publications Verification
Cat. No.: HY-N1724
CAS No.: 80890-47-7
Synonyms: Antibiotic X 4357B; Folimycin; X 4357B
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H +-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research - .
loading...
    loading...
28
28 Publications Verification
Cat. No.: HY-N1724A
CAS No.: 80890-47-7
Synonyms: Antibiotic X 4357B (purity≥70%); Folimycin (purity≥70%); X 4357B (purity≥70%)
Concanamycin A (purity≥70%) (Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H +-ATPase (V-ATPase) inhibitor. Concanamycin A (purity≥70%) is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research - .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-16379
CAS No.: 937272-79-2
Synonyms: SB1518
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM).
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-16379B
CAS No.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3

Research Areas:  

Cancer

Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-119706
CAS No.: 356568-70-2
Purity:  98.93%
Target:  

Apoptosis Arrestin

Research Areas:  

Others

Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-51424
CAS No.: 918505-84-7
Target:  

Raf

Research Areas:  

Cancer

PLX-4720 is a potent and selective inhibitor of B-Raf V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf V600E than wild-type B-Raf.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-156498
CAS No.: 2765082-12-8
Purity:  99.48%
Research Areas:  

Cancer

RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-114421
CAS No.: 2064175-41-1
Purity:  99.89%
Synonyms: dTAG-13
Research Areas:  

Cancer

FKBP12 PROTAC dTAG-13 (dTAG-13) is a FKBP12 F36V PROTAC degrader and a PXR partial agonist. FKBP12 PROTAC dTAG-13 induces ubiquitination and proteasomal degradation of proteins tagged with FKBP12 F36V, without degrading wild-type FKBP12 or un-fused PXR. It weakly promotes the recruitment of SRC-1, strongly inhibits the interaction between NCoR and PXR, and upregulates the expression of CYP3A4 and other drug metabolism-related genes. FKBP12 PROTAC dTAG-13 is applicable to research related to breast cancer and leukemia [1] .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-100818
CAS No.: 1448169-71-8
Purity:  99.65%
Synonyms: TAS-120
Target:  

FGFR

Research Areas:  

Cancer

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-13775
CAS No.: 945755-56-6
Purity:  99.65%
Target:  

JAK Apoptosis

Research Areas:  

Cancer

XL019?is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N0502
CAS No.: 88901-36-4
Mogroside V is a the major active constituent of a traditional Chinese medicine Siraitiae Fructus. Mogroside V reduces the intracellular reactive oxygen species (ROS) levels and enhances mitochondrial function. Mogroside V has anti-oxidative, anti-diabetic and anti-carcinogenic effects. Mogroside V can be used for diabetic diseases research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14852
CAS No.: 594839-88-0
Purity:  99.89%
Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14852A
CAS No.: 951395-08-7
Purity:  99.79%
Synonyms: Fx-1006A
Target:  

Transthyretin (TTR)

Research Areas:  

Neurological Disease

Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103195
CAS No.: 299442-43-6
Purity:  99.76%
Target:  

Adenylate Cyclase

Research Areas:  

Metabolic Disease

NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC50s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-E70005E
CAS No.: 9001-12-1
Target:  

MMP

Research Areas:  

Others

Collagenase, Type V is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type V breaksdown collagens1, 3, 5, 7, 8, 10, fibronectin, gelatin, aggrecann .

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-130173
CAS No.: 88979-61-7
Purity:  ≥99.0%
Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H +-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15011
CAS No.: 162045-26-3
Purity:  99.24%
Target:  

Oxytocin Receptor

Research Areas:  

Others

L-372662 is a potent and orally active non-peptide oxytocin antagonist with a Ki value of 4.8. The Kd value of L-372662 for wild-type hOTR and [A318G]OTR is 5.8 nM and 73 nM. L-372662 shows selectivity to OTR:V1aR .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72428
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: V-Type immunoglobulin domain-containing suppressor of T-cell activation; Vsir; Dies1; PD-1H; VISTA
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P0003
CAS No.: 124584-08-3
Synonyms: Brain Natriuretic Peptide-32 human; BNP-32
Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury .
loading...
    loading...